Related Experiment Video
Updated: Jun 9, 2026
07:56
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
Published on: August 18, 2010
Targeting tumor gene by shRNA-expressing Salmonella-mediated RNAi
1Skip Ackerman Center for Molecular Therapeutics, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. guohn2000@gmail.com
Gene Therapy
|September 3, 2010
Summary
Engineered Salmonella bacteria deliver short hairpin RNAs (shRNAs) to effectively silence the CTNNB1 gene. This RNA interference approach reduced cancer cell proliferation and tumor growth in preclinical models, offering a novel therapeutic strategy.
Area of Science:
- Molecular Biology
- Gene Therapy
- Microbiology
Background:
- RNA interference (RNAi) is a valuable research tool with therapeutic potential.
- Targeted in vivo induction of RNAi remains a significant challenge.
- Attenuated Salmonella enterica serovar typhimurium offers a novel delivery vector.
Purpose of the Study:
- To develop and evaluate an attenuated Salmonella strain for targeted RNA interference (RNAi) delivery.
- To assess the efficacy of shRNA-mediated CTNNB1 gene silencing in vitro and in vivo.
- To explore the therapeutic potential of this system for cancer treatment.
Main Methods:
- A pSLS plasmid expressing shRNAs was transformed into attenuated Salmonella (SL).
- In vitro studies used SW480 cells to assess CTNNB1 gene silencing and cellular effects.
- In vivo studies involved SW480 xenograft mice and APC(Min) mice to evaluate tumor and tissue gene expression.
Main Results:
- SL-pSLS-CAT effectively silenced CTNNB1 expression in SW480 cells, reducing proliferation and inducing cell death.
- CTNNB1 knockdown significantly inhibited tumor growth in xenograft mice.
- Gene expression of CTNNB1, c-Myc, and cyclin D1 was reduced in tumors and tissues of treated mice.
Conclusions:
- Attenuated, shRNA-expressing Salmonella represents a promising platform for in vitro gene silencing and functional genomics.
- This novel RNAi delivery system demonstrates potential for developing RNAi-based therapeutics against cancer and other diseases.
Related Concept Videos
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...